Home Blog Page 454

De Beers Group Launches New Bridal Campaign Celebrating Desert Diamonds

By
Advertorial Desk
-

NEW YORK, US – Media OutReach Newswire – 29 April 2026 – De Beers Group recently announced the launch of its new Desert diamonds Bridal campaign undersigned by A Diamond Is Forever, celebrating a fresh and authentic vision for the modern proposal. This campaign marks a significant moment in De Beers’ ongoing commitment to redefining how natural diamonds express individuality, love, and timeless beauty.

.

Desert diamonds, first unveiled as a beacon in October 2025, draw inspiration from the colors of the earth from which they originate. The campaign celebrates a unique spectrum of colors — each shade telling a story of resilience, authenticity, and enduring love. The bridal campaign will build upon the success and momentum of the Q4 Desert diamonds launch.

Evolving the modern bridal aesthetic and highlighting the distinct character of each stone, Desert diamonds’ warm hues echo diverse forms of love, with sunlit whites and champagnes, soft sand tones and sunset blush and dawn colors reflecting the uniqueness of nature’s beauty. Together, these colors celebrate the evolving journey of love in all its forms – authentic, true and timeless.

The Desert diamonds bridal campaign is an industry-wide umbrella program, the goal of which is to create demand for natural diamonds by reigniting consumer desire with a new and relevant message. Retailers and designers across the industry have been working to develop pieces that showcase the full desert-inspired palette, including notable jeweler Kindred Lubeck, who will unveil her first bridal collection in conjunction with the campaign launch.

Launching 13 April 2026 across the United States, De Beers’ A Diamond Is Forever Desert diamond bridal campaign is supported by an integrated marketing effort across digital, social, and experiential channels, while also including out-of-home, social media and publishing partnerships. Using evocative storytelling, that creative spotlights how each natural diamond is as unique as the love it represents. Premium targeting efforts across digital platforms and geotargeting around key retailers will result in an estimated reach of 25 million American consumers – placing Desert diamonds in bridal content while leveraging shopper data and look-a-like audiences. Further amplification across the Brides, Martha Stewart, and greater People Inc. portfolio will educate, inspire and reinforce Desert diamonds as the enduring choice.

Sandrine Conseiller, CEO of De Beers Brands & Diamond Desirability, said:
“The success of Desert diamonds reinforces the spirit of authentic, evolving love. Today’s brides want something truly unique that delivers meaning and individuality. Natural diamonds, forged by nature over billions of years, in a range of color choices are the perfect symbol of a love that is uniquely theirs – resilient, genuine, timeless, colorful. This soft palette of natural colors celebrates the modern couple’s desire to celebrate the individuality of their commitment and the promise of a forever that truly reflects their story.”

Hashtag: #DeBeersGroup #Desertdiamonds #DesertBridal #adiamondisforever #naturaldiamonds #diamonds





The issuer is solely responsible for the content of this announcement.

About De Beers Group

Established in 1888, De Beers Group is the world’s leading diamond company with expertise in the exploration, mining, marketing and retailing of diamonds. Together with its joint venture partners, De Beers Group employs more than 20,000 people across the diamond pipeline and is the world’s largest diamond producer by value, with diamond mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of De Beers Group’s strategy as it develops a portfolio of offers that span the diamond value chain, including its jewellery houses, De Beers London and Forevermark, and other pioneering solutions such as diamond sourcing and traceability initiatives Tracr and GemFair. De Beers Group also provides leading services and technology to the diamond industry in the form of education and laboratory services and a wide range of diamond sorting, detection and classification technology services. De Beers Group is committed to ‘Building Forever,’ a holistic and integrated approach to sustainability that underpins our efforts to create meaningful impact for the people and places where our diamonds are discovered. Building Forever focuses on three key areas where, through collaborations and partnerships around the globe, we have an enhanced ability to drive positive impact; Livelihoods, Climate and Nature. De Beers Group is a member of the Anglo American plc group. For further information, visit www.debeersgroup.com.

CIBF 2026: The World’s Largest Battery Show Lands in Shenzhen — Powering the Global Green Energy Revolution

By
Advertorial Desk
-

TIANJIN, China, April 29, 2026 /PRNewswire/ — The 18th China International Battery Fair (CIBF 2026) will take place May 13–15 at Shenzhen World Exhibition & Convention Center, as the definitive global event shaping the future of battery technology, energy storage, and low‑carbon innovation.

This year’s edition will welcome more than 3,100 global exhibitors — a new record in scale and diversity — covering the full battery value chain: power batteries, energy storage systems, 3C cells, advanced materials, intelligent manufacturing equipment, system solutions, and circular recycling technologies. Attendees will experience breakthrough innovations firsthand, from solid‑state and sodium‑ion batteries to smart production lines and carbon‑tracking systems, defining the next era of energy storage.

Alongside the exhibition, a series of high‑profile forums will convene over 2,000 industry leaders, researchers, and policymakers to explore cutting‑edge themes: next‑generation battery technology, electric aviation batteries, large‑scale energy storage deployment, and carbon footprint management. These sessions deliver exclusive insights into policy direction, tech breakthroughs, and global market trends.

CIBF 2026 places green development at its core, spotlighting fuel cells, low‑carbon manufacturing, and recycling solutions to support zero‑carbon industrial parks and global sustainability goals.

China’s battery industry posted strong results in 2025: export volume remained steady, while export value surged 22.8% to $82.279 billion, driven by high‑value lithium‑ion products that now account for 93.3% of total exports. The sector’s shift to quality, efficiency, and high‑end manufacturing underscores its global leadership.

As the ultimate hub connecting policy, industry, technology, and global markets, CIBF 2026 is now open for visitor pre‑registration. It is the must‑attend event for anyone pursuing partnerships, innovation, and growth in the global battery and green energy ecosystem.

For details, visit the official site: https://www.cibf.org.cn/en-US

Promotional graphic for the 18th China International Battery Fair (CIBF 2026), welcoming attendees to the event held from May 13–15, 2026, at the Shenzhen World Exhibition & Convention Center
Promotional graphic for the 18th China International Battery Fair (CIBF 2026), welcoming attendees to the event held from May 13–15, 2026, at the Shenzhen World Exhibition & Convention Center

 

Newmark Deepens Engagement in South Korea Through AMCHAM Leadership Appointments

By
Advertorial Desk
-

John Pritchard appointed Chair of the Real Estate Committee and to the Board of Governors; Newmark joins as Founding Partner, the chamber’s highest membership tier

SEOUL, Korea, April 29, 2026 /PRNewswire/ — Newmark continues to strengthen its long-term presence in South Korea through a series of leadership appointments within the American Chamber of Commerce in Korea (AMCHAM Korea), reinforcing the firm’s active participation and engagement with clients, stakeholders and the broader business community.

Newmark Group, Inc.
Newmark Group, Inc.

John Pritchard, Country Head, South Korea, has been appointed Chair of AMCHAM Korea’s Real Estate Committee and named to its Board of Governors, positioning Newmark at the center of key business and policy discussions shaping the country’s commercial real estate landscape. In parallel, Newmark has joined AMCHAM Korea as a Founding Partner, the chamber’s highest tier of membership, further supporting the firm’s expanding presence and engagement in-market.

Pritchard’s leadership roles place Newmark within a prominent forum for dialogue between Korean and U.S. businesses, reinforcing the firm’s ability to remain closely connected to the priorities of corporate occupiers, investors and other market participants. As Chair of the Real Estate Committee, he will help guide conversations around market trends, capital flows and the evolving needs of clients operating in South Korea and across Asia Pacific. This engagement is further supported by Newmark’s Founding Partner membership, which reflects a deeper level of participation within AMCHAM Korea’s network of leading U.S. and multinational companies operating in the market.

“John’s appointment as Chair of the Real Estate Committee and to the Board of Governors reflects his leadership and deep understanding of Korea’s real estate landscape,” said James Kim, Chairman and Chief Executive Officer of AMCHAM Korea. “We are pleased to welcome him into these roles and look forward to his contributions in advancing industry dialogue and promoting greater U.S.-Korea cross-border investment. We also welcome Newmark in Korea as a Founding Partner and value the firm’s expanded engagement with AMCHAM’s community.”

Pritchard added, “These appointments reflect the momentum of our business in South Korea and the importance of being actively engaged in the conversations shaping our market as connected, globally informed experts. AMCHAM Korea provides an important platform for collaboration and dialogue, and I look forward to contributing in these roles while continuing to support our clients across the region.”

About Newmark

Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2025, Newmark generated revenues of nearly $3.3 billion. As of December 31, 2025, Newmark and its business partners together operated from approximately 175 offices with over 9,300 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark

Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/newmark_group_logo_v1-1.jpg

Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

By
Advertorial Desk
-
  • Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.
  • The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.
  • Rentosertib inhalation solution is the 13th program from Insilico’s AI-driven pipeline to receive IND clearance, further demonstrating how Pharma.AI could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.

CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ — Insilico Medicine ( “Insilico”, HKEX:3696 ), a clinical-stage, generative AI–driven drug discovery company, today announced that the inhalation solution of Rentosertib (ISM001-055), the company’s first-in-class drug candidate with AI-identified novel target and AI-developed molecule structure, received IND clearance from CDE. Notably, Rentosertib inhalation solution is the 13th program from Insilico’s AI-driven pipeline to receive IND clearance, further demonstrating how Pharma.AI could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.

The IND clearance supports a Phase I study to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of Rentosertib inhalation solution. The study will consist of two parts: (1) a randomized, double-blind, placebo-controlled Phase I trial in healthy participants involving single ascending dose (SAD) and multiple ascending dose (MAD) cohorts; and (2) a non-randomized, open-label evaluation in patients with Idiopathic Pulmonary Fibrosis (IPF) receiving multiple doses. Approximately 80 subjects are expected to be enrolled.

“We are pleased to receive CDE IND approval for Rentosertib inhalation solution.” says Feng Ren, Ph.D., Co-CEO and CSO of Insilico Medicine. “In prior clinical studies, oral Rentosertib showed good tolerability, a favorable PK profile, and dose-dependent efficacy trend, strengthening our confidence in its mechanism and clinical potential. We look forward to seeing the Rentosertib inhalation solution deliver positive clinical results again in both healthy volunteers and patient populations. The inhalation solution is designed for targeted lung delivery, with the goal of achieving higher pulmonary exposure and faster onset at lower doses while reducing systemic exposure and optimizing the benefit–risk profile. In parallel, we continue to advance the oral Rentosertib program and remain on track to initiate Phase III trials in the second half of this year.”

Administration by inhalation is a complex drug delivery technology that requires combining formulation and devices, presenting higher technical barriers. Inhalation solutions deliver treatment as vapor or aerosol through special devices into the respiratory tract (i.e. the target organ), which is considered one of the most efficient routes of drug delivery as it may provide advantages including rapid action onset, high bioavailability, lowered effective dose and reduced side effects with a noninvasive and targeted route of administration.

In preclinical studies, the inhalation solution of Rentosertib was able to achieve higher lung exposure with low systemic exposure and demonstrated antifibrotic and anti-inflammatory efficacy in animal models. Moreover, it showed good pharmacokinetic (PK) and safety profiles, as well as good stability and solubility.

“The CDE IND clearance for the Rentosertib inhalation solution further validates Insilico Medicine’s sustainable, scalable, and reproducible AI-driven drug discovery and development workflow.” says Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. “With our proprietary AI models, we empower the whole process from target discovery to clinical development, expanding into formulation types and geographic areas. To date, we have successfully nominated 30 preclinical candidate compounds (DC/PCC), with the latest emerging from the UAE, a country with no prior history of innovative drug development. At the same time, Insilico Medicine has initiated three Phase II clinical trials and achieved IND clearance for 13 programs across fibrosis, oncology, immunology, and central nervous system disorders.”

Insilico Medicine has established AI-driven drug discovery partnerships with global leading companies, including Eli Lilly, Hygtia Therapeutics, Qilu Pharmaceutical, CMS, TaiGen, ASKA Pharma, Tenacia, Fosun Pharma, and Sanofi, and has achieved important R&D milestones across multiple collaborations. By integrating advanced AI and automation technologies, Insilico Medicine has demonstrated significant efficiency improvements in practical applications, setting a benchmark for AI-driven drug research and development. Compared to the typical 4.5 years required in traditional drug discovery, Insilico’s 20+ nominated candidate drugs from 2021 to 2024 took only 12–18 months on average to progress from project initiation to nomination of preclinical candidates (PCCs), with each project requiring synthesis and testing of only about 60–200 molecules.

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, scarring lung disease characterized by a progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis, with a median survival of 3 to 4 years. Current approved treatments, including antifibrotic drugs, can slow disease progression but do not stop or reverse it, leaving a significant unmet need for more effective, disease-modifying therapies.

About Rentosertib (Known asISM001-055)

Rentosertib is a potentially first-in-class small-molecule TNIK inhibitor, discovered and developed with the support of Insilico’s proprietary generative AI platform, Pharma.AI. The FDA granted Orphan Drug Designation(ODD) to Rentosertib for the treatment of IPF in February 2023. The CDE granted Breakthrough Therapy Designation (BTD) to Rentosertib in May 2025.

Rentosertib’s early drug discovery and development process was completed in 18 months with less than 80 small molecules synthesized and tested. This dramatically shortens traditional R&D timeline through AI-enabled target identification and molecule design. The AI-driven workflow was reported in  Nature Biotechnology in March 2024. More importantly, Rentosertib achieved the world’s first proof-of-concept for the efficacy of AI-driven drug discovery with the positive results demonstrated in the GENSIS-IPF Phase IIa trial, and the results were published in Nature Medicine in June 2025.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

DB HiTek to Participate in PCIM 2026, Strengthening Its Presence in the European Market

By
Advertorial Desk
-
  • Europe’s largest power semiconductor exhibition to be held in Nuremberg, Germany, from June 9 to 11
  • Showcasing latest developments in SiC and GaN, highlighting its power semiconductor capabilities

SEOUL, South Korea, April 29, 2026 /PRNewswire/ — DB HiTek, a leading 8-inch pure-play foundry, announced its participation in PCIM (Power Conversion and Intelligent Motion) Europe 2026, the continent’s premier exhibition for power semiconductors. The event will take place in Nuremberg, Germany, from June 9 to 11 (local time), as the company continues expanding its presence in the European market.

Following its successful debut at PCIM in 2025—where the company held face-to-face meetings with dozens of customers to discuss process technologies and collaboration opportunities—DB HiTek is building on that momentum. With over 1,000 booth visitors last year and ongoing business discussions, the company expects these engagements to translate into tangible business results this year through continued partnerships.

At this year’s event, DB HiTek will present progress in its next-generation SiC (Silicon Carbide) and GaN (Gallium Nitride) processes. The company will also highlight its industry-leading BCDMOS (Bipolar-CMOS-DMOS) technology, a core strength of its power management portfolio. A robust schedule of meetings with global clients is already in place, reflecting continued growth in collaboration.

According to market research firm Yole Développement, the global SiC and GaN power semiconductor markets are set for rapid growth. The SiC market is projected to grow from approximately $4.8 billion in 2026 to $10.4 billion by 2030, representing a compound annual growth rate (CAGR) of 21%. Over the same period, the GaN market is expected to expand from $900 million to $2.9 billion, reflecting a CAGR of 33%.

DB HiTek started MPW (Multi-Project Wafer) runs for its SiC and GaN processes in December 2025, producing samples for more than 10 customer products. These were delivered between March and April 2026. Customer evaluations are underway, with feedback to be incorporated into final process verification. Full-scale mass production is scheduled to begin in 2027.

Currently, DB HiTek maintains mass production relationships with approximately 400 customers, primarily focused on its flagship power semiconductor products. The company also works with a broad client base using specialized image sensor technologies, including X-ray, Global Shutter, and SPAD (Single Photon Avalanche Diode). Its application mix is increasingly shifting toward industrial and automotive-grade products, reflecting growing demand from these sectors.

World first for endangered frogs facing extinction

By
Advertorial Desk
-

Littlejohn’s Tree Frogs breed within 72 hours of arrival at WILD LIFE Sydney Zoo

Download high-res images and vision here.

SYDNEY, April 29, 2026 /PRNewswire/ — WILD LIFE Sydney Zoo has announced a groundbreaking achievement in conservation with the success of its first-ever on-site breed for release program. Within just 72 hours of arriving at a new custom-built facility, endangered frog species Littlejohn’s Tree Frogs (Litoria littlejohni) have successfully produced three clutches of eggs, a milestone never before achieved in a zoo setting.


 


 


The achievement is the result of over a year of preparation in partnership with the University of Newcastle’s Centre of Conservation Science and Amphibian ICU. The Littlejohn’s Tree frog is an elusive native species facing imminent extinction, with threats such climate change, extreme habitat loss and degradation, and chytrid disease – an amphibian fungus which affects many Australian frog species. The impact of these threats has led to small and isolated populations, with reduced genetic diversity and therefore decreased reproduction and survival rates of tadpoles and metamorphs. 

The species is now found in only three remaining locations in the New South Wales Sydney Basin from the Watagan State Forest to the Woronora Plateau, and only with five fragmented populations.

The zoo received a cohort of 58 frogs from the University of Newcastle’s Centre for Conservation Research and Amphibian ICU, including 22 wild founder individuals and 36 sub-adults hatched at the University last winter.

Ashley Wombey, Curatorial Manager Conservation, Population and Science said: “It has been over 12 months of preparation, which has included building a purpose-built breeding facility affectionately naming our “Frogservation Lab”, installing life support systems with continual testing and monitoring to provide the ideal parameters that reflect their wild habitat.  The speed at which the frogs have displayed breeding behaviours tells us they have settled very quickly and that we have provided the perfect conditions for them to flourish. Not only is their arrival exciting, it is an important step in safeguarding the future of the species.  We are very excited to partner with the University of Newcastle, as the future of conservation is through collaboration.”

Dr Alex Callen from the University of Newcastle’s Amphibian ICU within the Centre for Conservation Science said: “The achievement is very exciting as it is only the second time that this species has been bred in human care. This Littlejohn’s tree frog breeding program focuses on improving the genetic diversity of the species as it now occurs from only three isolated regions in the world.” 

By establishing this breeding colony in the heart of Sydney, the zoo is ensuring that even if wild populations continue to decline, a genetically diverse “insurance population” is ready to be returned to the wild.

While a number of tadpoles have already hatched, they are in a sensitive stage of development. The zoo team is monitoring the remaining eggs closely, with more hatchlings anticipated within the next couple of weeks.

Visitors can learn more about this exciting project and get a glimpse of the “Frogservation Lab” now at WILD LIFE Sydney Zoo.

About Merlin Entertainments Merlin Entertainments is a world leader in branded entertainment destinations across the UK, US, Western Europe, China, and Asia Pacific. Dedicated to creating experiences that inspire joy and connection, Merlin welcomes more than 62 million guests annually to its growing estate, with over 140 sites across 23 countries.

 

LG Display’s 27-inch DFR Gaming OLED panel wins SID’s ‘Display of the Year’

By
Advertorial Desk
-

SEOUL, South Korea, April 29, 2026 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced that its 27-inch 540/720Hz Dynamic Frequency & Resolution (DFR) Gaming OLED panel has been awarded “Display of the Year” by the Society for Information Display (SID), receiving high acclaim for redefining the gaming display paradigm and accelerating market differentiation.

LG Display’s 27-inch DFR Gaming OLED panel wins SID’s ‘Display of the Year’
LG Display’s 27-inch DFR Gaming OLED panel wins SID’s ‘Display of the Year’

The “Display of the Year” award is SID’s most prestigious distinction, presented to the most groundbreaking display product launched during the previous year that is expected to lead the future of the industry.

This achievement recognizes LG Display’s new user-centered display paradigm. The product’s standout feature is the company’s proprietary DFR technology, which allows users to freely select the mode that suits their preferred gaming style.

High-refresh-rate mode particularly proves its value in game genres where rapid screen transitions are essential and victory is decided in a split second — like first-person shooters or racing games. By supporting an industry-leading refresh rate of 720Hz with HD resolution, this mode eliminates ghosting and motion blur even in the fastest scenes, enabling overwhelming gaming performance.

High-resolution mode provides an optimized visual experience for games based on stunning graphics. It simultaneously delivers QHD resolution and a 540Hz refresh rate. To overcome the conventional limitation where picture quality drops once the refresh rate exceeds 500Hz, LG Display applied a proprietary algorithm, securing the two core elements of a high refresh rate and high picture quality.

As a result, the panel obtained ClearMR 21000 certification, the highest rating from the Video Electronics Standards Association (VESA).

“Our goal is to continue leading the gaming display market by leveraging LG Display’s differentiated OLED technologies and relentless pursuit of innovation,” said Young-seok Choi, Chief Technology Officer of LG Display.

SID is the world’s largest display society with more than 7,000 industry experts, researchers, and professors. It hosts Display Week annually, featuring new technologies, product exhibitions, and academic presentations. SID Display Week 2026 will take place in Los Angeles, California from May 3 to 8.

※ LG Display 27-inch 540/720Hz (DFR) OLED Gaming Monitor Panel Specifications

Category

High-refresh-rate mode

High-resolution mode

Peak Brightness

1,500nits

1,500nits

Refresh Rate / Resolution

720Hz / HD

540Hz / QHD

Response Time

0.02ms

0.02ms

 

About LG Display
LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Team Leader, Communication Team
Email: hjy05@lgdisplay.com

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

By
Advertorial Desk
-

TAIPEI, April 29, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it has advanced the market access strategies for its innovative plant-based drugs Botreso® and PCP, after an analysis of their clinical efficacy and competitive advantages.

As previously announced, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech’s innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs.

Safety Profile for Long-Term Use

For middle-aged and elderly men requiring long-term medication, safety is one of the most decisive factor. During the clinical trials – a one-year medication period for Botreso® (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability.

In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021.

Addressing the Risk of High-Grade Prostate Cancer

Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score ≥ 7) when cancer does occur, raising significant clinical safety concerns.

The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world’s first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies.

Comprehensive “Treatment + Prevention + Metabolic Management”

Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning:

  • Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates.
  • Prostate Cancer Prevention: Demonstrates preventative clinical potential.
  • Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P<0.05) , significantly increases HDL (good cholesterol) (P<0.05) , and maintains stable blood sugar.

This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40.

Technological Barriers and Competitive Advantages

Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes:

  • The purification and establishment of reference standards.
  • The development and validation of analytical methods.
  • The execution of validation analyses and verification processes.

The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity.

Upgraded Market Positioning and Strategic Value

As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages:

  • Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets.
  • Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships.
  • Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management.

Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at $4.1 billion in 2020, is projected to reach $9.8 billion by 2026. While the current treatment market generates approximately $6.5 to $7 billion annually, this figure reflects price reductions due to patent expirations; if valued at on-patent pricing, this market potential exceeds $20 billion annually*.

“Due to their complex composition, botanical new drugs present significant quality control challenges compared to small-molecule chemical drugs,” stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “We have established a robust technology platform encompassing the purification of standard references, the development and validation of analytical methods, and the execution of validation analysis. This high barrier to entry makes imitation difficult, mitigates generic competition, and helps extend the period of market exclusivity.”

“Botreso® is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials,” Kuo said. “Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion.”

As of present day, Botreso® and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

*Data source: BMC Urology 2025 (Global Epidemiology); IMARC BPH market report; P&S Intelligence market data; Global Market Statistics; Grand View Research (device market); Market Analytics (drug segmentation).

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

1...453454455...6,484Page 454 of 6,484